Welcome to our dedicated page for TScan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on TScan Therapeutics stock.
TScan Therapeutics, Inc. (NASDAQ: TCRX) is a pioneering biopharmaceutical company focused on developing advanced T-cell receptor (TCR) engineered T cell therapies (TCR-T) aimed at treating cancer. Specializing in harnessing novel T cell systems, TScan is at the forefront of extending the promise of immunotherapy to patients with hematologic malignancies and solid tumors.
The company's leading therapies, TSC-100 and TSC-101, are designed to eliminate residual leukemia and prevent relapse in patients with blood cancers such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) undergoing hematopoietic stem cell transplantation. These liquid tumor TCR-T therapy candidates are currently in development, reflecting TScan's commitment to improving patient outcomes.
TScan is also developing multiplexed TCR-T therapy candidates for treating various solid tumors, showcasing the company's versatility and innovative approach in the immunotherapy landscape. Recent recognition includes the RMAT designation granted for both TSC-100 and TSC-101, highlighting their potential significance in cancer treatment.
In addition to its groundbreaking therapeutic developments, TScan Therapeutics maintains strong partnerships and a robust financial foundation. The company frequently updates its stakeholders through transparent communication and investor relations, ensuring that all relevant developments and milestones are promptly shared.
For the latest news and updates, you can contact Heather Savelle, VP of Investor Relations, at 857-399-9840 or via email at hsavelle@tscan.com. Further inquiries can also be directed to Joyce Allaire, Managing Director at LifeSci Advisors, LLC, at 617-435-6602 or jallaire@lifesciadvisors.com.
FAQ
What is the current stock price of TScan Therapeutics (TCRX)?
What is the market cap of TScan Therapeutics (TCRX)?
What is TScan Therapeutics, Inc.?
What are TScan's leading therapy candidates?
What recent recognition has TScan's therapies received?
What types of cancer does TScan focus on?
How does TScan aim to improve cancer treatment?
How can I contact TScan's Investor Relations?
Where can I get the latest updates about TScan?
What is the stock symbol for TScan Therapeutics, Inc.?
Who are the key contacts for media inquiries at TScan?
What are TScan's goals in immunotherapy?
